{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:49:31Z","timestamp":1782107371289,"version":"3.54.5"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Platinum-resistant ovarian cancer (PROC) is a major challenge in gynecological tumor treatment, with poor prognosis and limited chemotherapy efficacy. Immune checkpoint inhibitors as monotherapy demonstrate low response rates, underscoring the need for effective combination therapies. This review aims to describe recent advances in immune combination therapy for PROC, explain synergistic mechanisms, summarize key clinical evidence, and discuss challenges and future directions. The search of PubMed and Web of Science (January 2018\u2013January 2026) following PRISMA guidelines identified phase II\/III trials, prospective cohorts, and preclinical studies. The narrative review found that combination strategies with anti-angiogenic agents achieved objective response rates (ORR) of 24\u201327% and median progression-free survival (PFS) of 4\u20135 months. Adding PARP inhibitors yielded an ORR of 18\u201331% with disease control rates of 65\u201381%. Furthermore, the antibody-drug conjugate (ADC) mirvetuximab soravtansine as monotherapy achieved an ORR of 42.3% in folate receptor alpha (FR\u03b1)-high PROC. Finally, the phase III KEYNOTE B96 trial reported a 4.2-month overall survival benefit with pembrolizumab plus chemotherapy in the PD-L1-positive population. These regimens substantially improve efficacy compared with historical single-agent chemotherapy (ORR 10\u201320%, PFS 3\u20134 months). In conclusion, immune combination therapy offers a novel therapeutic strategy for PROC. Future efforts should explore biomarkers, optimize regimens, overcome resistance, and validate efficacy through innovative trials to achieve personalized treatment.<\/jats:p>","DOI":"10.3389\/fonc.2026.1792883","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:39:32Z","timestamp":1782106772000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A narrative review of new strategies for immunotherapy combination treatment in platinum-resistant ovarian cancer: mechanisms, clinical evidence, and future directions"],"prefix":"10.3389","volume":"16","author":[{"given":"Lili","family":"Zhang","sequence":"first","affiliation":[{"name":"Inner Mongolia Medical University, Department of Obstetrics and Gynecology, Affiliated Hospital of Inner Mongolia Medical University","place":["Inner Mongolia, Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ma","sequence":"additional","affiliation":[{"name":"Inner Mongolia Medical University, Department of Thyroid and Breast Surgery, Affiliated Hospital of Inner Mongolia Medical University","place":["Inner Mongolia, Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Affiliated Hospital of Inner Mongolia Medical University","place":["Inner Mongolia, Hohhot, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100629","article-title":"Epithelial ovarian cancer: Review article","volume":"33","author":"Sambasivan","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"B5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/igc.0b013e3182049273","article-title":"Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube","volume":"21","author":"Griffiths","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjog.2024.05.006","article-title":"Evolving treatment paradigms for platinum-resistant ovarian cancer: An update narrative review","volume":"63","author":"Lin","year":"2024","journal-title":"Taiwan J Obstet Gynecol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ijgc-00009577-200505001-00004","article-title":"Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma","volume":"15","author":"Rose","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/ogx.0000000000000980","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","article-title":"PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer","volume":"141","author":"Webb","year":"2016","journal-title":"Gynecol Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/jci45817","article-title":"Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors","volume":"122","author":"Salmon","year":"2012","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2019.09.009","article-title":"Fibroblasts fuel immune escape in the tumor microenvironment","volume":"5","author":"De Jaeghere","year":"2019","journal-title":"Trends Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3109\/08820139.2012.695417","article-title":"PGE(2)-driven induction and maintenance of cancer-associated myeloid-derived suppressor cells","volume":"41","author":"Obermajer","year":"2012","journal-title":"Immunol Invest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-12-4354","article-title":"Vascular normalization as an emerging strategy to enhance cancer immunotherapy","volume":"73","author":"Huang","year":"2013","journal-title":"Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41568-021-00413-6","article-title":"Overcoming TGF\u03b2-mediated immune evasion in cancer","volume":"22","author":"Tauriello","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190418","article-title":"Biology and therapeutic potential of interleukin-10","volume":"217","author":"Saraiva","year":"2020","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nrc.2017.86","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.08.016","article-title":"Metabolic competition in the tumor microenvironment is a driver of cancer progression","volume":"162","author":"Chang","year":"2015","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00541-y","article-title":"Metabolic barriers to cancer immunotherapy","volume":"21","author":"DePeaux","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.it.2016.01.002","article-title":"IDO in the tumor microenvironment: Inflammation, counter-regulation, and tolerance","volume":"37","author":"Munn","year":"2016","journal-title":"Trends Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aak9670","article-title":"Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade","volume":"9","author":"Schmittnaegel","year":"2017","journal-title":"Sci Transl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003831","article-title":"Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study","volume":"10","author":"Xia","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2147\/ijwh.s502665","article-title":"Efficacy and safety of low-dose lenvatinib and toripalimab in patients with recurrent platinum-resistant ovarian cancer: Study protocol of a multicenter, open-label, single-arm, phase II clinical trial","volume":"17","author":"Su","year":"2025","journal-title":"Int J Womens Health"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.06.023","article-title":"Low-dose lenvatinib plus toripalimab for patients with platinum-resistant recurrent ovarian cancer: preliminary results from a multicenter, phase II trial (NCT06241105)","volume":"199","author":"Su","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Haanen","year":"2018","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00306","article-title":"Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: Placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39)","volume":"39","author":"Moore","year":"2021","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7277","article-title":"Association and prognostic significance of BRCA1\/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1\/PD-L1 in high grade serous ovarian cancer","volume":"7","author":"Strickland","year":"2016","journal-title":"Oncotarget"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-1218","article-title":"PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer","volume":"9","author":"Pantelidou","year":"2019","journal-title":"Cancer Discov"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-15-0044","article-title":"CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer","volume":"3","author":"Higuchi","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m115.661611","article-title":"Poly(ADP-ribosyl)ation of FOXP3 protein mediated by PARP-1 protein regulates the function of regulatory T cells*","volume":"290","author":"Luo","year":"2015","journal-title":"J Biol Chem"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/1078-0432.ccr-23-2249","article-title":"Olaparib plus durvalumab, with or without bevacizumab, as treatment in PARP inhibitor-na\u00efve platinum-sensitive relapsed ovarian cancer: A phase II multi-cohort study","volume":"30","author":"Drew","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-23-0051","article-title":"Phase II window study of olaparib alone or with cisplatin or durvalumab in operable head and neck cancer","volume":"3","author":"Moutafi","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.009","article-title":"Dostarlimab and niraparib in primary advanced ovarian cancer","volume":"36","author":"Hardy-Bessard","year":"2025","journal-title":"Ann Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.11.020","article-title":"Durvalumab with carboplatin\/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer","volume":"37","author":"Harter","year":"2025","journal-title":"Ann Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)01040-2","article-title":"Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial","volume":"405","author":"Olawaiye","year":"2025","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B48","article-title":"Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy","volume":"62","author":"Nowak","year":"2002","journal-title":"Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.12.009","article-title":"Outcomes and long-term follow-up by treatment type for patients with advanced-stage ovarian cancer managed at a tertiary cancer center: A Memorial Sloan Kettering Cancer Center Team Ovary study","volume":"169","author":"Ehmann","year":"2023","journal-title":"Gynecol Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2022.103488","article-title":"MiR-624-5p enhances NLRP3 augmented gemcitabine resistance via EMT\/IL-1\u03b2\/Wnt\/\u03b2-catenin signaling pathway in ovarian cancer","volume":"150","author":"Alrashed","year":"2022","journal-title":"J Reprod Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-365825","article-title":"Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells","volume":"118","author":"Obermajer","year":"2011","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.5483\/bmbrep.2023-0024","article-title":"Immunogenic cell death in cancer immunotherapy","volume":"56","author":"Choi","year":"2023","journal-title":"BMB Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.27436","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody-drug conjugates (ADCs) for personalized treatment of solid tumors: a review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"M\u00fcller","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030394","article-title":"Acquired resistance to antibody-drug conjugates","volume":"11","author":"Collins","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/01.ogx.0000943180.30391.de","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"157","author":"O'Malley","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ygyno.2025.06.016","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer","volume":"200","author":"Matulonis","year":"2025","journal-title":"Gynecol Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial","volume":"20","author":"de Bono","year":"2019","journal-title":"Lancet Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3391188","article-title":"Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer","volume":"26","author":"Hong","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-12-2243","article-title":"New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential","volume":"19","author":"Banerjee","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02085","article-title":"First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors","volume":"38","author":"Hassan","year":"2020","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2022-003927","article-title":"Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study","volume":"33","author":"Santin","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_390772","article-title":"Antibody-drug conjugates in gynecologic cancer","volume":"43","author":"Karpel","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.101978","article-title":"Antibody-drug conjugates in gynecologic cancer: current landscape, clinical data, and emerging targets","volume":"35","author":"He","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01761-9","article-title":"Cadonilimab: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: a key inhibitor of the cancer immunity cycle","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2025.101785","article-title":"Patient with HR-proficient advanced ovarian cancer achieved a complete response with Cadonilimab combined chemotherapy (PD-1\/CTLA-4 bispecific): a case report and literature review","volume":"60","author":"Zhang","year":"2025","journal-title":"Gynecol Oncol Rep"},{"key":"B73","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2017-06-741041","article-title":"Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies","volume":"131","author":"Chester","year":"2018","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.7150\/thno.76854","article-title":"Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy","volume":"12","author":"Liu","year":"2022","journal-title":"Theranostics"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-24-0190","article-title":"Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy","volume":"14","author":"Chand","year":"2024","journal-title":"Cancer Discov"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.34213","article-title":"Current progress in CAR-T cell therapy for solid tumors","volume":"15","author":"Ma","year":"2019","journal-title":"Int J Biol Sci"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers","volume":"25","author":"Stevanovi\u0107","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2167189","article-title":"The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy","volume":"15","author":"Claus","year":"2023","journal-title":"MAbs"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005301","article-title":"First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)","volume":"11","author":"Postel-Vinay","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.11.020","article-title":"Durvalumab with carboplatin\/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer","volume":"37","author":"Harter","year":"2026","journal-title":"Ann Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1136\/ijgc-2020-001572","article-title":"Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29\/ENGOT-ov34)","volume":"30","author":"Harter","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(26)00602-1","article-title":"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study","volume":"407","author":"Colombo","year":"2026","journal-title":"Lancet"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2024.100009","article-title":"Can we learn from failures? A systematic review of phase III trials in platinum-resistant ovarian cancer","volume":"35","author":"Martorana","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"B85","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41467-022-28389-3","article-title":"Single-cell tumor-immune microenvironment of BRCA1\/2 mutated high-grade serous ovarian cancer","volume":"13","author":"Launonen","year":"2022","journal-title":"Nat Commun"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1277308","article-title":"Clear cell ovarian cancers with microsatellite instability: a unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1\/PD-L1 expression","volume":"6","author":"Howitt","year":"2017","journal-title":"Oncoimmunology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.4287","article-title":"Towards the introduction of the 'Immunoscore' in the classification of Malignant tumours","volume":"232","author":"Galon","year":"2014","journal-title":"J Pathol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1172\/jci91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B89","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-24-3209","article-title":"Mannose enhances immunotherapy efficacy in ovarian cancer by modulating gut microbial metabolites","volume":"85","author":"Zhang","year":"2025","journal-title":"Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002198","article-title":"Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study","volume":"13","author":"Parkinson","year":"2016","journal-title":"PloS Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s41747-023-00364-7","article-title":"Ovarian cancer beyond imaging: integration of AI and multiomics biomarkers","volume":"7","author":"Hatamikia","year":"2023","journal-title":"Eur Radiol Exp"},{"key":"B93","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1186\/s12967-025-06872-x","article-title":"ImmuProgML: machine learning-based dissection of cancer-immune dynamics during tumor progression to improve immunotherapy","volume":"23","author":"Zhou","year":"2025","journal-title":"J Transl Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s10238-025-01902-w","article-title":"Beyond single biomarkers: multi-omics strategies to predict immunotherapy outcomes in blood cancers","volume":"25","author":"Pirouzbakht","year":"2025","journal-title":"Clin Exp Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","article-title":"Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy","volume":"167","author":"Gao","year":"2016","journal-title":"Cell"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B99","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2","volume":"10","author":"Lan","year":"2018","journal-title":"Sci Transl Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","article-title":"Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1","volume":"71","author":"Cha","year":"2018","journal-title":"Mol Cell"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1417636112","article-title":"Immune-mediated antitumor effect by type 2 diabetes drug, metformin","volume":"112","author":"Eikawa","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B103","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.2316","article-title":"The platform trial: an efficient strategy for evaluating multiple treatments","volume":"313","author":"Berry","year":"2015","journal-title":"Jama"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"Jama"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0167-7","article-title":"Real-world data: towards achieving the achievable in cancer care","volume":"16","author":"Booth","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1200\/jop.18.00005","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.04.011","article-title":"Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: results from the phase 2 multicohort LEAP-005 study","volume":"186","author":"Gonz\u00e1lez-Mart\u00edn","year":"2024","journal-title":"Gynecol Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2026.37.e49","article-title":"The role of chemo-immunotherapy in platinum-resistant ovarian cancer in light of the KEYNOTE-B96 trial","volume":"37","author":"Bogani","year":"2026","journal-title":"J Gynecol Oncol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70251","article-title":"Immunochemotherapy regimen demonstrates survival benefits for patients with platinum-resistant ovarian cancer","volume":"132","author":"Lawrence","year":"2026","journal-title":"Cancer"},{"key":"B114","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1158\/1078-0432.ccr-24-3128","article-title":"Randomized phase II study of bevacizumab with weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant\/refractory high-grade ovarian cancer (NCI trial)","volume":"31","author":"Alqaisi","year":"2025","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1792883\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:39:34Z","timestamp":1782106774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1792883\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":114,"alternative-id":["10.3389\/fonc.2026.1792883"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1792883","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1792883"}}